An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.